Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ROMOSOZUMAB-AQQG Cause Hepatic function abnormal? 17 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 17 reports of Hepatic function abnormal have been filed in association with ROMOSOZUMAB-AQQG. This represents 0.2% of all adverse event reports for ROMOSOZUMAB-AQQG.

17
Reports of Hepatic function abnormal with ROMOSOZUMAB-AQQG
0.2%
of all ROMOSOZUMAB-AQQG reports
1
Deaths
11
Hospitalizations

How Dangerous Is Hepatic function abnormal From ROMOSOZUMAB-AQQG?

Of the 17 reports, 1 (5.9%) resulted in death, 11 (64.7%) required hospitalization, and 1 (5.9%) were considered life-threatening.

Is Hepatic function abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ROMOSOZUMAB-AQQG. However, 17 reports have been filed with the FAERS database.

What Other Side Effects Does ROMOSOZUMAB-AQQG Cause?

Fall (646) Fracture (612) Arthralgia (517) Injection site pain (490) Bone density abnormal (454) Off label use (419) Hospitalisation (381) Headache (360) Product storage error (348) Death (263)

What Other Drugs Cause Hepatic function abnormal?

NIVOLUMAB (1,131) PEMBROLIZUMAB (1,079) METHOTREXATE (1,054) CABOZANTINIB S-MALATE (912) CYCLOPHOSPHAMIDE (824) BEVACIZUMAB (769) PACLITAXEL (603) LENVATINIB (528) ATORVASTATIN (520) CYCLOSPORINE (508)

Which ROMOSOZUMAB-AQQG Alternatives Have Lower Hepatic function abnormal Risk?

ROMOSOZUMAB-AQQG vs ROPEGINTERFERON ALFA-2B-NJFT ROMOSOZUMAB-AQQG vs ROPINIROLE ROMOSOZUMAB-AQQG vs ROPIVACAINE ROMOSOZUMAB-AQQG vs ROSIGLITAZONE ROMOSOZUMAB-AQQG vs ROSUVASTATIN

Related Pages

ROMOSOZUMAB-AQQG Full Profile All Hepatic function abnormal Reports All Drugs Causing Hepatic function abnormal ROMOSOZUMAB-AQQG Demographics